Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, PMID: 25693012
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, PMID: 22153890
Pertuzumab and trastuzumab: the rationale way to synergy, PMID: 27275646
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, PMID: 32171426
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, PMID: 22149875
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), PMID: 23704196
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, PMID: 23602601
Pertuzumab for the treatment of breast cancer, PMID: 30884986
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study, PMID: 29253081
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial, PMID: 29175149
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial, PMID: 31647503
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE), PMID: 30796821
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab, PMID: 32917240
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study, PMID: 28056202
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study, PMID: 30217672
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study, PMID: 33357420
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial, PMID: 30106636
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer, PMID: 29223479
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study, PMID: 31157583
Pertuzumab, Trastuzumab and Hyaluronidase-zzxf, PMID: 32997754
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial, PMID: 32988996
Pertuzumab in HER2-positive early breast cancer: current use and perspectives, PMID: 30938542
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study, PMID: 32564260
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients, PMID: 31830538
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle, PMID: 28092723
Pertuzumab: optimizing HER2 blockade, PMID: 23942091
Pertuzumab for the treatment of breast cancer: a safety review, PMID: 26982349
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, PMID: 15093539
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study, PMID: 30570763
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis, PMID: 31638935
Pertuzumab in gastrointestinal cancer, PMID: 26619359
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group, PMID: 31126258
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE, PMID: 31318460
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study, PMID: 27964843
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 28770452
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer, PMID: 28183321
Pertuzumab: development beyond breast cancer, PMID: 24692675
Pertuzumab in HER2-positive breast cancer, PMID: 22953713
Pertuzumab in the treatment of HER2+ breast cancer, PMID: 24717573
Pertuzumab for the treatment of ovarian cancer, PMID: 20465533
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer, PMID: 31146717
Pertuzumab in breast cancer: a systematic review, PMID: 23810292
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study, PMID: 29326029
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer, PMID: 31953696
Pertuzumab for the treatment of breast cancer, PMID: 24921704
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study, PMID: 27306421
Safety and efficacy evaluation of pertuzumab in patients with solid tumors, PMID: 28514302
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex, PMID: 31042744
Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer, PMID: 22316351
Pertuzumab: Getting the Balance Right, PMID: 29895630
For research use only. Not for human or drug use.
